Novo Nordisk Signals Aggressive Hunt for Deals to Expand GLP-1 Pipeline
TL;DR Summary
Novo Nordisk CEO says the company is actively pursuing acquisitions to broaden its GLP-1 pipeline amid growing competition in obesity drugs, citing assets like CagriSema and zenagamtide; Wegovy's strong Q1 performance lifted full-year guidance, even as Eli Lilly overtook Novo in weekly GLP-1 market share.
Reading Insights
Total Reads
1
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
89%
426 → 45 words
Want the full story? Read the original article
Read on CNBC